ALK and lung carcinoma: Patients of ALK rearrangement lung cancer shows drug resistance to lorlatinib; these mechanisms include epitheilial-mesogenic transition susceptible to combined ALK/Src inhibition, ALK compound mutations, and a novel bypass mechanism, mediated by Nf2 loss and outcome by mtor inhibition (141).